Benjamin Gregory Carlisle
Benjamin Gregory Carlisle
Verified email at - Homepage
Cited by
Cited by
Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials
B Carlisle, J Kimmelman, T Ramsay, N MacKinnon
Clinical Trials 12 (1), 77-83, 2015
Benefit, risk, and outcomes in drug development: a systematic review of sunitinib
B Carlisle, N Demko, G Freeman, A Hakala, N MacKinnon, T Ramsay, ...
JNCI: Journal of the National Cancer Institute 108 (1), 2016
Inefficiencies and patient burdens in the development of the targeted cancer drug sorafenib: a systematic review
J Mattina, B Carlisle, Y Hachem, D Fergusson, J Kimmelman
PLoS biology 15 (2), e2000487, 2017
Rethinking Research Ethics: The Case of Postmarketing Trials
AJ London, J Kimmelman, B Carlisle
Science 336 (6081), 544-545, 2012
Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials
A Hakala, J Kimmelman, B Carlisle, G Freeman, D Fergusson
Bmj 350, 2015
Trials that say “maybe”: the disconnect between exploratory and confirmatory testing after drug approval
B Carlisle, CA Federico, J Kimmelman
Bmj 360, 2018
Proof of prespecified endpoints in medical research with the bitcoin blockchain
BG Carlisle
The Grey Literature 25, 2014
Drug development at the portfolio level is important for policy, care decisions and human protections
J Kimmelman, B Carlisle, M Gönen
Jama 318 (11), 1003-1004, 2017
Imatinib and the long tail of targeted drug development
BG Carlisle, T Zheng, J Kimmelman
Nature Reviews Clinical Oncology 17 (1), 1-3, 2020
Numbat meta-analysis extraction manager
BG Carlisle
Late, never or non‐existent: the inaccessibility of preclinical evidence for new drugs
CA Federico, B Carlisle, J Kimmelman, DA Fergusson
British journal of pharmacology 171 (18), 4247-4254, 2014
Impact of precision medicine on efficiencies of novel drug development in cancer
H Sarvas, B Carlisle, S Dolter, E Vinarov, J Kimmelman
JNCI: Journal of the National Cancer Institute 112 (8), 859-862, 2020
Benefit, burden, and impact for a cohort of post-approval cancer combination trials
BG Carlisle, A Doussau, J Kimmelman
Clinical Trials 17 (1), 18-29, 2020
Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study
BG Carlisle, A Doussau, J Kimmelman
BMJ open 10 (2), e034306, 2020
How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence?
M Pratte, S Ganeshamoorthy, B Carlisle, J Kimmelman
International journal of cancer 145 (12), 3370-3375, 2019
Cancer Precision Medicine Drug Development is Often Empirical: The Case of Imatinib, Dasatinib and Nilotinib
BG Carlisle, T Zheng, J Kimmelman
The moral efficiency of clinical trials in anti-cancer drug development, 53, 2019
Recapping the recent plagiarism scandal
B Carlisle
The informativeness of trials in Covid-19: Lessons learned from the Coronavirus pandemic
N Hutchinson, BG Carlisle, K Klas, J Kimmelman, M Polak, M Waligora
Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
N Hutchinson, B Carlisle, A Doussau, R Bosan, E Gumnit, A MacPherson, ...
JAMA network open 4 (5), e2110456-e2110456, 2021
How Informative were Early SARS-CoV-2 Treatment and Prevention Trials? A longitudinal cohort analysis of trials registered on clinicaltrials. gov
N Hutchinson, K Klas, BG Carlisle, J Kimmelman, M Waligora
medRxiv, 2021
The system can't perform the operation now. Try again later.
Articles 1–20